Indian IPO Historical Performance: Listing Gains Data for US Investors

stoicHQ tracks 40+ historical Indian mainboard IPOs with actual listing gain data, GMP history, QIB subscription figures, and sector breakdowns. Here is what the data shows -- and what it means for NRI and US investors who want to understand how Indian IPOs actually perform at listing.

Our Dataset -- 40+ IPOs with Real Listing Data

The stoicHQ historical IPO database covers mainboard IPOs from 2021-2025. We track:

• Issue price and listing price (NSE)
• Listing gain or loss as a percentage of issue price
• GMP history (day-by-day in the week before listing)
• QIB subscription multiple, NII subscription multiple, retail subscription multiple
• Anchor investor lineup
• Sector classification

We track mainboard IPOs only. SME IPOs are excluded -- grey market activity on SME IPOs is thin and manipulation risk is significantly higher. Browse the full database at Past IPOs.

Listing Gain Distribution

Listing gain range	IPOs in range	Examples
Below issue price (negative)	~15-20%	Paytm (listed at -27%), LIC (listed at -9%)
0% to 10% gain	~15-20%	Modest listers -- typically large-cap, fully priced
10% to 25% gain	~25-30%	Healthy listers -- Devyani International, JSW Infrastructure
25% to 50% gain	~20-25%	Strong listers -- Campus Activewear, Mankind Pharma
Above 50% gain	~10-15%	Exceptional listers -- Anthem Biosciences (90%+), Nykaa

The median listing gain across our tracked mainboard IPOs is approximately 15-20% above issue price. The distribution is right-skewed -- a small number of exceptional listers pull the average above the median.

GMP Accuracy Analysis

GMP (Grey Market Premium) is the most widely watched pre-listing signal. Here is how it performs as a predictor in our dataset:

GMP signal at listing day	Directional accuracy (correct listing direction)	Notes
GMP positive (any amount)	~65-70%	Positive GMP correctly predicts above-issue listing most but not all of the time
GMP negative	~80-85%	Negative GMP is a stronger, more reliable signal -- IPO listing below issue in most cases
GMP 0 or flat	~50%	Near-zero GMP is essentially a coin flip -- no useful signal

GMP is a directional signal, not a price target. A GMP of Rs 50 on a Rs 500 issue price does not mean the listing price will be exactly Rs 550 -- it means the grey market expects above-issue performance. The actual magnitude varies widely.

Sector Breakdown of Listing Gains

Sector	IPOs tracked	Avg listing gain	Notable performers
Pharma / CDMO / Healthcare	5+	~35-40%	Anthem Biosciences (90%+), Mankind Pharma (25%+)
Capital markets / Financial services	4+	~25-30%	KFin Technologies, BSE
QSR / Retail / Consumer	5+	~15-20%	Devyani International, Campus Activewear
Renewable energy	3+	~20-25%	Waaree Energies, IREDA
IT / Engineering services	4+	~10-15%	Tata Technologies, Ideaforge
Large conglomerate / Platform	3+	Mixed (wide range)	Paytm (-27%), Zomato (+52%), LIC (-9%)

Pharma and capital market IPOs have consistently shown above-median listing performance in our dataset. Large conglomerate platform IPOs have been the most variable -- high subscriptions do not always translate to strong listings.

QIB Subscription as a Corroborating Signal

When QIB (Qualified Institutional Buyer) subscription is high alongside positive GMP, the combined signal is more reliable than either alone:

• QIB above 50x + positive GMP: Strong correlation with above-median listing gains in our dataset
• QIB below 5x + positive GMP: GMP may be inflated -- treat with skepticism
• QIB above 20x + negative GMP: Rare, but worth extra scrutiny -- institutional appetite exists despite grey market pessimism

What US Investors and NRIs Should Note About These Numbers

• Listing gain % is pre-TDS for NRIs. A 30% listing gain translates to approximately 24% after 20% STCG TDS deduction -- the net gain is what hits your account.
• Currency risk applies. All gains are in INR. If you repatriate to the USA, the INR/USD exchange rate at the time of repatriation affects your USD return. INR has historically depreciated against USD over long periods.
• Repatriation is capped for NRO accounts. If your IPO investment was through an NRO-linked demat, repatriation is subject to the $1M annual limit. Use NRE accounts for IPO investing if repatriation is a priority.
• These are listing day gains only. Post-listing performance varies widely. Some IPOs that listed strongly gave back gains within weeks (Paytm); others that listed modestly continued compounding (Zomato).

How to Use This Data for IPO Subscription Decisions

The data above is historical and descriptive -- not predictive. Use it to calibrate your expectations, not as a guarantee of future performance. The five-signal framework for evaluating any specific IPO:

1. GMP trend (direction and magnitude in the 7 days before listing)
2. QIB subscription level (above 10x is minimum threshold for confidence)
3. Anchor investor quality (domestic MFs like SBI, HDFC, Mirae are stronger than foreign-only anchors)
4. Promoter quality and pledging (below 20% pledging is safer)
5. Use of IPO proceeds (fresh capital is better than pure OFS / promoter exit)

Track live GMP at the GMP tracker. See upcoming IPOs at upcoming IPOs India. Browse historical IPO data at Past IPOs.

Frequently Asked Questions

What is the average listing gain for Indian IPOs?

Based on stoicHQ's database of 40+ mainboard IPOs from 2021-2025, the median listing gain is approximately 15-20% above issue price on listing day. The distribution is wide -- some IPOs listed at 90%+ premiums (Anthem Biosciences) while others listed below issue price (Paytm, LIC). Median is a better reference than average due to the skewed distribution.

How accurate is GMP at predicting Indian IPO listing prices?

GMP is directionally accurate for mainboard IPOs roughly 65-70% of the time. It is more reliable as a negative signal: when GMP is negative at listing day, the IPO lists below issue price in over 80% of tracked cases. GMP is much less reliable for SME IPOs where grey market activity is thin and manipulation risk is higher.

What is the after-TDS listing gain for NRI investors in Indian IPOs?

NRIs pay 20% TDS on short-term capital gains (held under 12 months) on Indian equity IPO listings. If an IPO lists at 30% above issue price, the after-TDS gain is approximately 24% (30% minus 20% TDS on the 30% gain). For NRE account holdings, the net gain is freely repatriable after TDS deduction.

Which sector has produced the highest IPO listing gains in India?

Based on stoicHQ's IPO database, pharma/CDMO IPOs (Anthem Biosciences: 90%+ listing gain) and capital markets/financial services IPOs have shown the highest average listing gains among tracked mainboard IPOs from 2021-2025. QSR and retail IPOs have been more mixed. Platform/large conglomerate IPOs have the widest variance.

stoicHQ is not a SEBI-registered investment adviser, SEC-registered adviser, or FINRA member. Past IPO performance does not predict future results. This content is for educational and informational purposes only.